HK JIE XI INTERNATIONAL GENETIC TECHNOLOGY CO.,LIMITED – Trademark Portfolio
Entity Type: 99
HK JIE XI INTERNATIONAL GENETIC TECHNOLOGY CO.,LIMITED holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include USECUREAL. The owner is based in HONG KONG.
RM.20, RM.03, 7/F, BLK.B, TUEN MUN IND.
CENTRE, 2 SAN PING ST., TUEN MUN
HONG KONG 999077 , CN
Showing of trademarks Trademarks
Trademark Classifications
HK JIE XI INTERNATIONAL GENETIC TECHNOLOGY CO.,LIMITED's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does HK JIE XI INTERNATIONAL GENETIC TECHNOLOGY CO.,LIMITED have?
HK JIE XI INTERNATIONAL GENETIC TECHNOLOGY CO.,LIMITED has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does HK JIE XI INTERNATIONAL GENETIC TECHNOLOGY CO.,LIMITED file in?
HK JIE XI INTERNATIONAL GENETIC TECHNOLOGY CO.,LIMITED files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are HK JIE XI INTERNATIONAL GENETIC TECHNOLOGY CO.,LIMITED's most well-known trademarks?
HK JIE XI INTERNATIONAL GENETIC TECHNOLOGY CO.,LIMITED's registered trademark portfolio includes well-known marks such as USECUREAL. These are among 1 currently registered trademark in the portfolio.
What is HK JIE XI INTERNATIONAL GENETIC TECHNOLOGY CO.,LIMITED's trademark registration success rate?
HK JIE XI INTERNATIONAL GENETIC TECHNOLOGY CO.,LIMITED has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.